[S-24-1] Therapies for PD via modifying actions of extracellular alpha-synuclein

Seung-Jae Lee (Department of Biomedical Sciences, Seoul National University College of Medicine, Korea)

The concept of “disease modification” encompasses intervention types ranging from those designed to slow the underlying degeneration to treatments aiming at compensating lost neuronal functions. It is the ultimate goal of Parkinson disease treatment, although all attempts to develop effective disease-modifying therapy have failed to date. Many reasons have been proposed for these failures including our poor understanding of disease pathogenesis and the lack of sensitive surrogate markers of PD. Moreover, several observations suggest that the PD is not a single disease, but syndrome based on a variety of pathophysiological mechanisms. However, recently several promising new approaches have been reported and attracted attentions. The aim of this symposium is to elucidate true possibilities and real limitations of such novel trials.

[S-24-2] Challenges in trials of disease modifying therapies in Parkinson disease

Camille Carroll^1,2 (1.University of Plymouth Faculty of Medicine and Dentistry, UK, 2.University Hospitals Plymouth NHS Trust, UK)

The concept of “disease modification” encompasses intervention types ranging from those designed to slow the underlying degeneration to treatments aiming at compensating lost neuronal functions. It is the ultimate goal of Parkinson disease treatment, although all attempts to develop effective disease-modifying therapy have failed to date. Many reasons have been proposed for these failures including our poor understanding of disease pathogenesis and the lack of sensitive surrogate markers of PD. Moreover, several observations suggest that the PD is not a single disease, but syndrome based on a variety of pathophysiological mechanisms. However, recently several promising new approaches have been reported and attracted attentions. The aim of this symposium is to elucidate true possibilities and real limitations of such novel trials.

[S-24-3] In silico drug screening by using GWAS-data for Parkinson's disease

Tatsushi Toda (Department of Neurology, Graduate School of Medicine, The University of Tokyo, Japan)

The concept of “disease modification” encompasses intervention types ranging from those designed to slow the underlying degeneration to treatments aiming at compensating lost neuronal functions. It is the ultimate goal of Parkinson disease treatment, although all attempts to develop effective disease-modifying therapy have failed to date. Many reasons have been proposed for these failures including our poor understanding of disease pathogenesis and the lack of sensitive surrogate markers of PD. Moreover, several observations suggest that the PD is not a single disease, but syndrome based on a variety of pathophysiological mechanisms. However, recently several promising new approaches have been reported and attracted attentions. The aim of this symposium is to elucidate true possibilities and real limitations of such novel trials.

[S-24-4] Cholinesterase inhibitor may improve PD prognosis

Toru Baba (Department of Neurology, Sendai-Nishitaga National Hospital, Japan)

The concept of “disease modification” encompasses intervention types ranging from those designed to slow the underlying degeneration to treatments aiming at compensating lost neuronal functions. It is the ultimate goal of Parkinson disease treatment, although all attempts to develop effective disease-modifying therapy have failed to date. Many reasons have been proposed for these failures including our poor understanding of disease pathogenesis and the lack of sensitive surrogate markers of PD. Moreover, several observations suggest that the PD is not a single disease, but syndrome based on a variety of pathophysiological mechanisms. However, recently several promising new approaches have been reported and attracted attentions. The aim of this symposium is to elucidate true possibilities and real limitations of such novel trials.